1-4 of 4
Waleed Haso, M.S
Close
Sort by
Journal Articles

41BBL-Based Activation and Expansion of Autologous Natural Killer Cells Results in Enhanced Activity Against Leukemia Including ALL

Ekta Kapadia, MD, Elad Jacoby, MD, Mark Kohler, MDPhD, Waleed Haso, M.S., Christopher Daniel Chien, PhD, Terry J Fry, MD
Journal: Blood
Blood (2014) 124 (21): 2293.
https://doi.org/10.1182/blood.V124.21.2293.2293
Published: 2014
Journal Articles

CD22-Targeted Chimeric Antigen Receptor (CAR) T Cells Containing The 4-1BB Costimulatory Domain Demonstrate Enhanced Persistence and Superior Efficacy Against B-Cell Precursor Acute Lymphoblastic Leukemia (ALL) Compared To Those Containing CD28

Waleed Haso, M.S, Haiying Qin, MS, Ling Zhang, Rimas J Orentas, PhD, Terry J Fry, MD
Journal: Blood
Blood (2013) 122 (21): 1431.
https://doi.org/10.1182/blood.V122.21.1431.1431
Published: 2013
Journal Articles

Pre-Clinical Development Of a Novel Chimerical Antigen Receptor Targeting High-Risk Pediatric ALL Over-Expressing Tslpr

Haying Qin, Cho Monica, Waleed Haso, M.S., Ling Zhang, David M. Barrett, MD/PhD, Rimas J Orentas, PhD, Stephan A. Grupp, MD, PhD, Terry J Fry, MD
Journal: Blood
Blood (2013) 122 (21): 2665.
https://doi.org/10.1182/blood.V122.21.2665.2665
Published: 2013
Journal Articles

A New High Activity Anti-CD22 Chimeric Antigen Receptor (CAR) Targeting B Cell Leukemia.

Waleed Haso, M.S., Daniel W. Lee, III, MD, Ira Pastan, MD, Dimiter S. Dimitrov, Ph.D, Crystal L Mackall, MD, Rimas J Orentas, PhD
Journal: Blood
Blood (2012) 120 (21): 2611.
https://doi.org/10.1182/blood.V120.21.2611.2611
Published: 2012